Bristol Myers Squibb Company (NYSE:BMY) Shares Acquired by Crossmark Global Holdings Inc.

Crossmark Global Holdings Inc. grew its position in Bristol Myers Squibb Company (NYSE:BMY - Free Report) by 13.4% during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 216,452 shares of the biopharmaceutical company's stock after acquiring an additional 25,638 shares during the period. Crossmark Global Holdings Inc.'s holdings in Bristol Myers Squibb were worth $13,201,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also made changes to their positions in BMY. Brighton Jones LLC boosted its holdings in shares of Bristol Myers Squibb by 33.4% in the fourth quarter. Brighton Jones LLC now owns 19,728 shares of the biopharmaceutical company's stock valued at $1,116,000 after acquiring an additional 4,935 shares in the last quarter. Bank Pictet & Cie Europe AG purchased a new stake in shares of Bristol Myers Squibb in the fourth quarter valued at about $13,094,000. Proficio Capital Partners LLC purchased a new stake in Bristol Myers Squibb during the fourth quarter worth about $240,000. Vestmark Advisory Solutions Inc. acquired a new position in Bristol Myers Squibb during the fourth quarter worth about $421,000. Finally, Callan Family Office LLC grew its position in Bristol Myers Squibb by 152.8% during the fourth quarter. Callan Family Office LLC now owns 11,639 shares of the biopharmaceutical company's stock worth $658,000 after buying an additional 7,035 shares during the period. Hedge funds and other institutional investors own 76.41% of the company's stock.

Insiders Place Their Bets

In related news, EVP Samit Hirawat purchased 4,250 shares of the business's stock in a transaction on Friday, April 25th. The shares were bought at an average price of $47.58 per share, with a total value of $202,215.00. Following the completion of the purchase, the executive vice president directly owned 83,513 shares in the company, valued at approximately $3,973,548.54. This trade represents a 5.36% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available at this hyperlink. 0.07% of the stock is currently owned by corporate insiders.

Bristol Myers Squibb Trading Down 0.9%

Shares of BMY traded down $0.42 on Monday, hitting $46.50. 10,683,820 shares of the stock traded hands, compared to its average volume of 12,874,008. The company has a quick ratio of 1.17, a current ratio of 1.28 and a debt-to-equity ratio of 2.65. The firm has a market capitalization of $94.63 billion, a P/E ratio of 17.42, a P/E/G ratio of 1.39 and a beta of 0.36. The stock's 50 day moving average is $47.73 and its two-hundred day moving average is $53.58. Bristol Myers Squibb Company has a 1 year low of $39.50 and a 1 year high of $63.33.

Bristol Myers Squibb (NYSE:BMY - Get Free Report) last announced its quarterly earnings data on Thursday, April 24th. The biopharmaceutical company reported $1.80 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.50 by $0.30. The business had revenue of $11.20 billion for the quarter, compared to the consensus estimate of $10.77 billion. Bristol Myers Squibb had a net margin of 11.38% and a return on equity of 87.62%. The company's quarterly revenue was down 5.6% compared to the same quarter last year. During the same quarter in the prior year, the firm posted ($4.40) earnings per share. As a group, sell-side analysts predict that Bristol Myers Squibb Company will post 6.74 earnings per share for the current year.

Bristol Myers Squibb Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, August 1st. Shareholders of record on Thursday, July 3rd will be paid a dividend of $0.62 per share. This represents a $2.48 dividend on an annualized basis and a yield of 5.33%. The ex-dividend date of this dividend is Thursday, July 3rd. Bristol Myers Squibb's dividend payout ratio is currently 92.88%.

Wall Street Analyst Weigh In

BMY has been the topic of several recent analyst reports. The Goldman Sachs Group restated a "neutral" rating and set a $55.00 target price (down from $67.00) on shares of Bristol Myers Squibb in a research report on Tuesday, April 8th. Piper Sandler initiated coverage on shares of Bristol Myers Squibb in a research report on Tuesday, April 22nd. They set an "overweight" rating and a $65.00 target price on the stock. Argus upgraded shares of Bristol Myers Squibb to a "hold" rating in a research report on Friday, April 25th. UBS Group lowered their target price on shares of Bristol Myers Squibb from $60.00 to $54.00 and set a "neutral" rating on the stock in a research report on Friday, April 11th. Finally, Cantor Fitzgerald restated a "neutral" rating and set a $55.00 target price on shares of Bristol Myers Squibb in a research report on Tuesday, April 22nd. Two research analysts have rated the stock with a sell rating, thirteen have assigned a hold rating, six have given a buy rating and two have issued a strong buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of "Hold" and an average target price of $58.00.

Bristol Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.